Predictive Value of Interim and End-of-Therapy 18F-FDG PET/CT in Patients with Follicular Lymphoma.

Content Provider	Europe PMC
Author	Boo, Sun Ha O, Joo Hyun Kwon, Soo Jin Yoo, Ie Ryung Kim, Sung Hoon Park, Gyeong Sin Choi, Byung Ock Jung, Seung Eun Cho, Seok-Goo
Abstract	Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality for response evaluation in FDG-avid lymphoma, but the prognostic value is not established in follicular lymphoma (FL). This study investigated the prognostic value of Deauville 5-point scale (D5PS) from paired interim PET/CT (PETInterim) and end-of-induction therapy PET/CT (PETEOI) in patients with FL. Methods FL staging and response assessment PET/CT images from 2013 to 2015 were retrospectively reviewed. PETInterim was performed 3 or 4 cycles after chemotherapy and PETEOI after 6 or 8 cycles. D5PS scores of 1, 2, and 3 were considered as negative (−), and scores 4 and 5 were considered as positive (+). Statistical analysis was done using Cox regression analysis, Kaplan–Meier survival analysis, and the log-rank test. Results Thirty-three patients with set of baseline, interim, and end-of-induction therapy PET/CT studies were included. Ten patients (30.3%) had progression. The median progression-free survival (PFS) was 38.8 months (range 3.5–72.7 months). On PETInterim, 23 patients were negative and 10 were positive. On PETEOI scans, 29 patients were negative, and 4 were positive. On multivariate analysis, PETEOI(−) was associated with longer PFS. PETInterim(+) and PETEOI(+) patients had a significantly shorter PFS than PETInterim(−) patients (39.9 months, 95% confidence interval [CI] 23.0–56.9, versus 55.5 months, 95% CI 49.7–61.2, p = 0.005) and PETEOI(−) patients (14.2 months, 95% CI 8.5–19.8, versus 60.5 months, 95% CI 52.1–69.0, p < 0.001). Conclusion For patients with FL, PETInterim and PETEOI response is predictive of PFS, and PETEOI(+) is an independent prognostic factor for progression of FL.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC6694342&blobtype=pdf
ISSN	18693474
Volume Number	53
DOI	10.1007/s13139-019-00602-0
PubMed Central reference number	PMC6694342
Issue Number	4
PubMed reference number	31456859
Journal	Nuclear Medicine and Molecular Imaging [Nucl Med Mol Imaging]
e-ISSN	18693482
Language	English
Publisher	Springer Berlin Heidelberg
Publisher Date	2019-06-29
Publisher Place	Berlin/Heidelberg
Access Restriction	Open
Rights License	© Korean Society of Nuclear Medicine 2019
Subject Keyword	Follicular lymphoma 18F-fluorodeoxyglucose Positron emission tomography Lugano classification Progression-free survival
Content Type	Text
Resource Type	Article
Subject	Radiology, Nuclear Medicine and Imaging